Featured guide
Begin with reasons to stop, not reasons to proceed.
Ibogaine is associated with potentially dangerous effects on cardiac rhythm and can interact with medicines and other substances. The U.S. Food and Drug Administration describes ibogaine as an unapproved drug and warns of serious risks including cardiac arrhythmias and death; its warning on the serious risks associated with ibogaine is a useful starting point for understanding why screening matters.
A useful assessment begins with a complete picture: current symptoms, known diagnoses, prescription and nonprescription medicines, supplements, recent substance use, and prior reactions to treatment. This is not a checklist that can determine eligibility by itself. It is a way to identify questions that should not be minimized or answered from memory alone.
- Known heart concerns: past fainting, palpitations, unexplained chest symptoms, diagnosed rhythm problems, structural heart disease, or a family history of sudden cardiac death need careful review.
- Medication exposure: every current or recently stopped medicine matters, including psychiatric medicines, pain medicines, antibiotics, antifungals, stimulants, and over-the-counter products.
- Medical instability: liver or kidney disease, seizure history, electrolyte imbalance, pregnancy, and acute illness can all change the risk picture.
- Incomplete information: uncertainty about a medication, dose, diagnosis, or recent substance use is itself a reason to slow down rather than guess.
Important distinction: wanting relief from substance use, trauma symptoms, or another difficult condition does not make ibogaine medically appropriate. The broader ibogaine risk and contraindication overview explains why a safety-first review should come before claims about possible benefit.
